Zelebrudomide (NX-2127)

July 9, 2026: Nurix Therapeutics (NASDAQ: NRIX) reported fiscal Q2 results (ended May 31, 2026) and highlighted a new global license/collaboration with Roche for its BTK degrader bexobrutideg (NX-5948). The deal provides a $700M upfront payment expected within 30 days after the agreement becomes effective and allows up to $2.3B total payments including milestones; development costs are split 40% Nurix/60% Roche, U.S. profits/losses shared 50/50, and Nurix receives tiered ex-U.S. royalties. Closing is subject to customary conditions including HSR and other antitrust clearances. The partners plan development across malignant hematology and expansion into immune-mediated/neurology indications, including planned Phase 2 studies in chronic spontaneous urticaria (CSU) and multiple sclerosis (MS).

Clinical updates at EHA 2026 from the ongoing NX-5948-301 Phase 1a/1b study in relapsed/refractory CLL/SLL showed durable responses and favorable tolerability; Phase 1a median PFS was 22.1 months and ORR 83%. Phase 1b ORR was 92.9% in Cohort 5 (18/19 on treatment) and 84.2% in Cohort 15 (19/20 on treatment).

Catalyst timing: enrollment continues in pivotal Phase 2 DAYBreak CLL-201 (aimed at potential Accelerated Approval submission); first patient dosing in Phase 3 DAYBreak CLL-306 (vs pirtobrutinib) is anticipated mid-2026; additional NX-5948-301 updates are expected at medical meetings during 2026. Nurix also presented CSU-focused preclinical/Phase 1 translational data at the 2026 Society for Investigative Dermatology meeting and is running a healthy-volunteer SAD/MAD tablet-formulation study to support future Phase 2 CSU/MS trials.